1. Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.
- Author
-
Sakane, Sadatsugu, Hikita, Hayato, Shirai, Kumiko, Sakamoto, Tatsuya, Narumi, Ryohei, Adachi, Jun, Kakita, Naruyasu, Yamada, Yukinori, Toyoda, Hidenori, Takahashi, Hirokazu, Suda, Goki, Kai, Machiko, Tahata, Yuki, Sakamori, Ryotaro, Kumazaki, Shusuke, Fukumoto, Kenji, Myojin, Yuta, Murai, Kazuhiro, Kodama, Takahiro, Tatsumi, Tomohide, Tomonaga, Takeshi, Sakamoto, Naoya, Morii, Eiichi, and Takehara, Tetsuo
- Subjects
Humans ,Male ,Female ,Middle Aged ,Biomarkers ,Proteomics ,Extracellular Matrix Proteins ,Extracellular Vesicles ,Calcium-Binding Proteins ,Liver Cirrhosis ,Fatty Liver ,Adult ,Aged ,Disease Progression - Abstract
BACKGROUND: There is a need for novel noninvasive markers for metabolic dysfunction-associated steatotic liver disease (MASLD) to stratify patients at high risk for liver-related events including liver cancer and decompensation. In the present study, we used proteomic analysis of proteins in extracellular vesicles (EVs) to identify new biomarkers that change with fibrosis progression and can predict the development of liver-related events. METHODS: We analyzed serum EVs from 50 patients with MASLD assessed for liver fibrosis by biopsy and identified proteins that altered with advanced fibrosis. A further evaluation was conducted on another cohort of 463 patients with MASLD with biopsy. RESULTS: Eight candidate proteins were identified by proteomic analysis of serum EVs. Among them, serum levels of Fibulin-3, Fibulin-1, and Ficolin 1 correlated with their EV levels. In addition, serum Fibulin-3 and serum Fibulin-1 levels changed significantly with advanced fibrosis. Using another cohort with biopsy, we found that the serum Fibulin-3 concentration was significantly greater in those with advanced fibrosis but that the serum Fibulin-1 concentration was not significantly different. Multivariate Cox proportional hazards analysis revealed that a higher Fibrosis-4 (FIB-4) index and higher serum Fibulin-3 concentration were independent risk factors for liver-related events. When the cutoff value for the serum Fibulin-3 concentration was 6.0 µg/mL according to the Youden index of AUROCs, patients with high serum Fibulin-3 significantly more frequently developed liver-related events than did other patients. Validation using another cohort of 226 patients with clinically diagnosed MASLD confirmed that high serum Fibulin-3 levels are associated with a greater frequency of liver-related events. CONCLUSIONS: Serum Fibulin-3 was identified as a biomarker for predicting liver-related events in patients with MASLD.
- Published
- 2024